Detail akcie Collegium Pharma online

Business Summary: Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company. The Company has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. Its portfolio also includes AZSTARYS (serdexmethylphenidate and dexmethylphenidate), a central nervous system (CNS) stimulant prescription medicine used for the treatment of ADHD in people six years of age and older.
Financial Summary: BRIEF: For the six months ended 30 June 2026, Collegium Pharmaceutical Inc revenues increased 8% to $393.4M. Net loss totaled $555K vs. income of $14.4M. Revenues reflect Jomay PM segment increase of 39% to $85M, Symproic segment increase of 10% to $7.2M. Net loss reflects General and administrative - Balancing increase of 31% to $167.6M (expense), Stock-based Compensation in SGA increase of 14% to $25.4M (expense).